Financhill
Back

Innate Pharma SA Quote, Financials, Valuation and Earnings

Innate Pharma SA Price Quote

$1.45
-0.18 (-11.04%)
(Updated: November 25, 2024 at 5:55 PM ET)

Innate Pharma SA Key Stats

Sell
27
Innate Pharma SA (IPHA) is a Sell

Day range:
$1.54 - $1.70
52-week range:
$1.29 - $3.15
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.92
P/B ratio:
4.27%

Volume:
8K
Avg. volume:
10.6K
1-year change:
-31.51%
Market cap:
$131.9M
Revenue:
$56.2M
EPS:
$-0.45

How Much Does Innate Pharma SA Make?

Is Innate Pharma SA Growing As A Company?

Data Unavailable

Innate Pharma SA Stock Price Performance

  • Did Innate Pharma SA Stock Go Up Last Month?
    Innate Pharma SA share price went down by -14.88% last month
  • Did IPHA's Share Price Rise Over The Last Year?
    IPHA share price fell by -31.51% over the past 1 year

What Is Innate Pharma SA 52-Week High & Low?

Innate Pharma SA Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Innate Pharma SA?

  • How Much Debt Does Innate Pharma SA Have?
    Total long term debt quarterly is $38.1M
  • How Much Cash Does Innate Pharma SA Have?
    Cash and short term investments quarterly total is $98.4M
  • What Is Innate Pharma SA’s Book Value Per Share?
    Book value per share is 0.38

Is Innate Pharma SA Cash Flow Positive?

  • What Is IPHA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$19.4M
  • What Is Innate Pharma SA’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$5.4M
  • What Is Innate Pharma SA’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $23.5M

Innate Pharma SA Return On Invested Capital

  • Is Management Doing A Good Job?
    IPHA return on invested capital is -39.78%
  • What Is Innate Pharma SA Return On Assets?
    ROA measures how assets are converting to revenues and is -18.89%
  • What Is IPHA Return On Equity?
    ROE is a measure of profitability and is -72.79%

Innate Pharma SA Earnings Date & Stock Price

Innate Pharma SA Competitors

Innate Pharma SA Dividend Yield

Innate Pharma SA Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 7.41
Upside from Last Price: 354.72%

Major Shareholders

  • How many IPHA shares are owned by institutional investors?
    349.1K IPHA shares are owned by institutional investors
  • How many IPHA shares are owned by insiders?
    0 IPHA shares are owned by insiders